WO1997033620A3 - Verbindungen zur behandlung von tumoren - Google Patents

Verbindungen zur behandlung von tumoren Download PDF

Info

Publication number
WO1997033620A3
WO1997033620A3 PCT/EP1997/001337 EP9701337W WO9733620A3 WO 1997033620 A3 WO1997033620 A3 WO 1997033620A3 EP 9701337 W EP9701337 W EP 9701337W WO 9733620 A3 WO9733620 A3 WO 9733620A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
icg
tumours
treating tumours
therapeutic treatment
Prior art date
Application number
PCT/EP1997/001337
Other languages
English (en)
French (fr)
Other versions
WO1997033620A2 (de
Inventor
Alwin Goetz
Ulrich Pfeiffer
Gabriela Puehler
Original Assignee
Pulsion Verw Gmbh & Co Medical
Alwin Goetz
Ulrich Pfeiffer
Gabriela Puehler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1996110348 external-priority patent/DE19610348A1/de
Application filed by Pulsion Verw Gmbh & Co Medical, Alwin Goetz, Ulrich Pfeiffer, Gabriela Puehler filed Critical Pulsion Verw Gmbh & Co Medical
Publication of WO1997033620A2 publication Critical patent/WO1997033620A2/de
Publication of WO1997033620A3 publication Critical patent/WO1997033620A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Indocyaningrün (ICG) oder ICG-Antikörperkonjugat, ggf. in Mischung mit üblichen Arzneimittelzusätzen oder -trägern, zur therapeutischen Behandlung von Tumoren, ihre Verwendung zur Herstellung von Arzneimitteln für die therapeutische Behandlung von Tumoren und die Verwendung von ICG zur Herstellung von Antikörperkonjugaten.
PCT/EP1997/001337 1996-03-15 1997-03-17 Verbindungen zur behandlung von tumoren WO1997033620A2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19610348.7 1996-03-15
DE1996110348 DE19610348A1 (de) 1996-03-15 1996-03-15 Verbindung zur Behandlung von Tumoren und deren Verwendung zur Herstellung von Arzneimitteln
DE19654186A DE19654186A1 (de) 1996-03-15 1996-12-23 Verbindungen zur Behandlung von Tumoren und deren Verwendung zur Herstellung von Arzneimitteln
DE19654186.7 1996-12-23

Publications (2)

Publication Number Publication Date
WO1997033620A2 WO1997033620A2 (de) 1997-09-18
WO1997033620A3 true WO1997033620A3 (de) 1998-02-05

Family

ID=26023855

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/001337 WO1997033620A2 (de) 1996-03-15 1997-03-17 Verbindungen zur behandlung von tumoren

Country Status (1)

Country Link
WO (1) WO1997033620A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0911023A1 (de) * 1998-03-20 1999-04-28 Mario Luca Russo Photosensibilisierende Stoffe enthaltende pharmazeutische oder kosmetische Zubereitung
WO2000041726A2 (en) * 1999-01-15 2000-07-20 Light Sciences Corporation Noninvasive vascular therapy
US6217848B1 (en) * 1999-05-20 2001-04-17 Mallinckrodt Inc. Cyanine and indocyanine dye bioconjugates for biomedical applications
FR2796295B1 (fr) * 1999-07-13 2001-10-05 Inst Nat Sante Rech Med Photocoagulateur laser a adaptation de fluence
US6944493B2 (en) 1999-09-10 2005-09-13 Akora, Inc. Indocyanine green (ICG) compositions and related methods of use
US6351663B1 (en) 1999-09-10 2002-02-26 Akorn, Inc. Methods for diagnosing and treating conditions associated with abnormal vasculature using fluorescent dye angiography and dye-enhanced photocoagulation
US6443976B1 (en) 1999-11-30 2002-09-03 Akorn, Inc. Methods for treating conditions and illnesses associated with abnormal vasculature

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0175617A2 (de) * 1984-09-13 1986-03-26 Cytogen Corporation Therapeutische Antikörpermittelkonjugate
DE3828360A1 (de) * 1988-08-20 1990-02-22 Stanowsky Alexander Dr Farbstoff-markierter antitumor-antikoerper und verfahren zu seiner herstellung
WO1992000106A2 (en) * 1990-06-27 1992-01-09 Diomed Limited Method of treatment and compositions therefore
WO1996031237A2 (en) * 1995-04-04 1996-10-10 Wound Healing Of Oklahoma Cancer treatment by photodynamic therapy, in combination with an immunoadjuvant
WO1997031582A1 (en) * 1996-02-29 1997-09-04 Cytopharm, Inc. A novel phototherapeutic method for treating cancer and/or dermatological diseases and conditions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0175617A2 (de) * 1984-09-13 1986-03-26 Cytogen Corporation Therapeutische Antikörpermittelkonjugate
DE3828360A1 (de) * 1988-08-20 1990-02-22 Stanowsky Alexander Dr Farbstoff-markierter antitumor-antikoerper und verfahren zu seiner herstellung
WO1992000106A2 (en) * 1990-06-27 1992-01-09 Diomed Limited Method of treatment and compositions therefore
WO1996031237A2 (en) * 1995-04-04 1996-10-10 Wound Healing Of Oklahoma Cancer treatment by photodynamic therapy, in combination with an immunoadjuvant
WO1997031582A1 (en) * 1996-02-29 1997-09-04 Cytopharm, Inc. A novel phototherapeutic method for treating cancer and/or dermatological diseases and conditions

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHEN, WEI R. ET AL: "Chromophore-enhanced in vivo tumor cell destruction using an 808-nm diode laser", CANCER LETT. (SHANNON, IREL.) (1995), 94(2), 125-31 CODEN: CALEDQ;ISSN: 0304-3835, 1995, XP002048130 *
CHEN, WEI R. ET AL: "Indocyanine green in-situ administration and photothermal destruction of tumor cells using an 808-nm diode laser", PROC. SPIE-INT. SOC. OPT. ENG. (1996), 2681(LASER-TISSUE INTERACTION VII), 94-101 CODEN: PSISDG;ISSN: 0277-786X, 1996, XP002048132 *
CHEN, WEI R. ET AL: "Laser-photosensitizer assisted immunotherapy: a novel modality for cancer treatment", CANCER LETT. (SHANNON, IREL.) (1997), 115(1), 25-30 CODEN: CALEDQ;ISSN: 0304-3835, 1997, XP002048135 *
CHEN, WEI R. ET AL: "Photothermal effects on murine mammary tumors using indocyanine green and an 808-nm diode laser: an in vivo efficacy study", CANCER LETT. (SHANNON, IREL.) (1996), 98(2), 169-73 CODEN: CALEDQ;ISSN: 0304-3835, 1996, XP002048131 *
FOLLI, SILVIO ET AL: "Antibody-indocyanin conjugates for immunophotodetection of human squamous cell carcinoma in nude mice", CANCER RES. (1994), 54(10), 2643-9 CODEN: CNREA8;ISSN: 0008-5472, 1994, XP002048134 *
GU, YING ET AL: "Selective protection of normal hepatocytes by indocyanine green in photodynamic therapy for the hepatoma of rat", PROC. SPIE-INT. SOC. OPT. ENG. (1993), 1616(INTERNATIONAL CONFERENCE ON PHOTODYNAMIC THERAPY AND LASER MEDICINE, 1991), 266-74 CODEN: PSISDG;ISSN: 0277-786X, 1993, XP002048133 *
MEW D ET AL: "PHOTO IMMUNO THERAPY TREATMENT OF ANIMAL TUMORS WITH TUMOR SPECIFIC MONO CLONAL ANTIBODY HEMATO PORPHYRIN CONJUGATES.", J IMMUNOL 130 (3). 1983. 1473-1477. CODEN: JOIMA3 ISSN: 0022-1767, XP002048136 *

Also Published As

Publication number Publication date
WO1997033620A2 (de) 1997-09-18

Similar Documents

Publication Publication Date Title
HU9602937D0 (en) Compositions comprising dna damaging agents and p53
MXPA02010801A (es) Agentes diagnosticos, de representacion y terapeuticos cationicos asociados con sitios vasculares activados.
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
WO1999038973A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
EP1308168A4 (de) NEUE HEILMITTEL FüR KREBS
WO1999033869A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO1999015167A3 (en) Use of citrus limonoids and flavonoids as well as tocotrienols for the treatment of cancer
WO1999029729A3 (en) Antagonists of neuropilin receptor function and use thereof
HUP9700579A2 (en) Novel prodrugs for treating tumors and flogistic diseases, pharmaceutical compns. contg. them and their preparation
NZ507350A (en) Semi-synthetic ecteinascidins and use in treatment of tumors
HUP0203238A3 (en) Drugs for the treatment of malignant tumours, process for their preparation and pharmaceutical compositions containing them
WO1999044608A8 (en) New use
WO1999022722A3 (en) Use of macrolides for the treatment of cancer and macular degeneration
WO1998008505A8 (en) Pharmaceutical compounds
WO1998009599A3 (fr) Utilisation d'un nouvel acide bicafeoylquinique dans le traitement de l'hepatite b et des maladies liees a des retrovirus, et derives de cet acide bicafeolyquinique
WO2000061756A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO1997033620A3 (de) Verbindungen zur behandlung von tumoren
WO2000013712A3 (en) Methods and compositions for the prevention or treatment of cancer
IL129927A0 (en) 1,4-Diazabicyclo (2.2.2) oct-2-ylmethyl derivatives their preparation and therapeutic application
GB9521608D0 (en) Pharmaceutical composition
EE200000333A (et) Eesnäärmevähi ravis kasutatav konjugaat ning farmatseutiline kompositsioon ja selle valmistamismeetod
AU4789099A (en) Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents
EP1208840A3 (de) Zusammensetzung zur Behandlung von Tumoren oder Krebs, welche Fluorouracil und ein Methylol Übertragungsmittel enthält

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97532300

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase